Lindsay Tomaszek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lindsay Tomaszek has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Pablo Adam
Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York, U.S.A.
2 shared publications - Ramon Bossardi Ramos
Department of Molecular and Cellular Physiology, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208
2 shared publications Dareen Chuy
Department of Molecular and Cellular Physiology and Albany Medical College
1 shared publicationNina Martino
Department of Molecular and Cellular Physiology and Albany Medical College
1 shared publication- Nina Martino
Department of Molecular and Cellular Physiology Albany Medical College Albany NY USA
1 shared publication - Shuhan Lu
Hastings Center for Pulmonary Research, Keck School of Medicine, University of Southern California, Los Angeles, USA
1 shared publication
Latest Publications
- Open Access
SOCS3 limits endotoxin-induced endothelial dysfunction by blocking a required autocrine interleukin 6 signal in human umbilical vein endothelial cells
Increased circulating levels of soluble interleukin (IL)-6 receptor α (sIL-6Rα) are commonly observed during inflammatory responses, allowing for IL-6 signaling to occur in cells that express the ubiquitous receptor subunit gp130 but not IL-6Rα, such as endothelial cells. Activation of Toll-like receptor (TLR)-4 or the tumor necrosis factor (TNF) receptor leads to NF-κB-dependent increases in endothelial IL-6 expression. Thus, we hypothesize that danger signals may induce autocrine IL-6 signaling within the endothelium via sIL-6Rα-mediated trans-signaling. In support of this hypothesis, we recently demonstrated that conditional deletion in the endothelium of the IL-6 signaling inhibitor SOCS3 leads to rapid mortality in mice challenged with the TLR-4 agonist endotoxin through increases in vascular leakage, thrombosis, leukocyte adhesion, and a type I-like interferon response. Here, we sought to directly test a role for sIL-6Rα in LPS-treated human umbilical vein endothelial cells. We show that cotreatment with sIL-6Rα dramatically increases the loss of barrier function and the expression of COX2 and tissue factor mRNA levels induced by LPS. This co-treatment led to a strong activation of STAT1 and STAT3 while not affecting LPS-induced activation of p38 and NF-κB signaling. Similar results were obtained when sIL-6Rα was added to a TNF challenge. JAK inhibition by pretreatment with ruxolitinib or by SOCS3 overexpression blunted LPS and sIL-6R synergistic effects, while SOCS3 knockdown further increased the response. Together, these findings demonstrate that IL-6 signaling downstream of NF-kB activation leads to a strong endothelial activation and may explain the acute endotheliopathy observed during critical illness.
Open AccessSOCS3 limits endotoxin-induced endothelial dysfunction by blocking a required autocrine interleukin 6 signal in human umbilical vein endothelial cells
Increased circulating levels of soluble interleukin (IL)-6 receptor α (sIL-6Rα) are commonly observed during inflammatory responses, allowing for IL-6 signaling to occur in cells that express the ubiquitous receptor subunit gp130 but not IL-6Rα, such as endothelial cells. Activation of Toll-like receptor (TLR)-4 or the tumor necrosis factor (TNF) receptor leads to NF-κB-dependent increases in endothelial IL-6 expression. Thus, we hypothesize that danger signals may induce autocrine IL-6 signaling within the endothelium via sIL-6Rα-mediated trans-signaling. In support of this hypothesis, we recently demonstrated that conditional deletion in the endothelium of the IL-6 signaling inhibitor SOCS3 leads to rapid mortality in mice challenged with the TLR-4 agonist endotoxin through increases in vascular leakage, thrombosis, leukocyte adhesion, and a type I-like interferon response. Here, we sought to directly test a role for sIL-6Rα in LPS-treated human umbilical vein endothelial cells. We show that cotreatment with sIL-6Rα dramatically increases the loss of barrier function and the expression of COX2 and tissue factor mRNA levels induced by LPS. This co-treatment led to a strong activation of STAT1 and STAT3 while not affecting LPS-induced activation of p38 and NF-κB signaling. Similar results were obtained when sIL-6Rα was added to a TNF challenge. JAK inhibition by pretreatment with ruxolitinib or by SOCS3 overexpression blunted LPS and sIL-6R synergistic effects, while SOCS3 knockdown further increased the response. Together, these findings demonstrate that IL-6 signaling downstream of NF-kB activation leads to a strong endothelial activation and may explain the acute endotheliopathy observed during critical illness.
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Role of endothelial SOCS3 in brain permeability and retinal vascular leukoembolization
Interleukin‐6 (IL‐6) is a major cytokine within the cytokine storm that occurs in response to severe systemic inflammation and sepsis. This cytokine promotes the activation of the JAK/STAT3 pathway. SOCS3, a protein induced by STAT3, acts as the main inhibitor this pathway. Prior work demonstrated that loss of SOCS3 in the endothelium of mice treated with LPS led to fast mortality within 16‐24 hours post‐challenge. The aim of this study is to determine the role of endothelial SOCS3 in brain permeability and retinal vascular leukoembolization in this severe, acute inflammatory model. We generated tamoxifen inducible SOCS3 knockout mice and induced severe acute inflammation by IP injection with LPS. Mice were evaluated for severity after 15 hours and euthanized for tissue collecting 16 hours after LPS injection. We found higher LPS‐induced severity in SOCS3iEKO mice compared to littermate controls. We observed significant weight loss after endotoxin, but surprisingly SOCS3iEKO mice displayed less weight loss, which could be due to fluid accumulation driven by increased systemic edema. Therefore, we interrogated whether SOCS3 loss promoted endothelial permeability. Lung and brain microvascular permeability was assayed by injecting FITC‐labeled 70kDa dextran 30 minutes prior to euthanasia and perfusion with PBS. Consistent with increased leakage, extravasated dextran was detected in thick (50‐100) um sections of LPS treated SOCS3iEKO mice. We hypothesized that this higher permeability could be due to increased leukocyte accumulation. In fact, we detected very high levels P‐selectin mRNA level in the kidneys, livers and lungs of LPS treated SOCS3iEKO mice, suggesting an increased adhesivity to leukocytes of the affected vasculature. To assess this, we stained flat mount retinas for P‐selectin and CD45 (pan‐leukocyte). LPS‐treated SOCS3iEKO mice showed a dramatic accumulation of intravascular leukocytes and increased P‐selectin expression. Intravascular leukocytes were also detected by standard H&E staining of lungs, livers and kidneys of SOCS3iEKO mice. In sum, we found that the lethality observed after a single endotoxin challenge in mice lacking endothelial SOCS3 is associated with increased intraluminal leukocyte adhesion and endothelial permeability.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessRole of endothelial SOCS3 in brain permeability and retinal vascular leukoembolization
Interleukin‐6 (IL‐6) is a major cytokine within the cytokine storm that occurs in response to severe systemic inflammation and sepsis. This cytokine promotes the activation of the JAK/STAT3 pathway. SOCS3, a protein induced by STAT3, acts as the main inhibitor this pathway. Prior work demonstrated that loss of SOCS3 in the endothelium of mice treated with LPS led to fast mortality within 16‐24 hours post‐challenge. The aim of this study is to determine the role of endothelial SOCS3 in brain permeability and retinal vascular leukoembolization in this severe, acute inflammatory model. We generated tamoxifen inducible SOCS3 knockout mice and induced severe acute inflammation by IP injection with LPS. Mice were evaluated for severity after 15 hours and euthanized for tissue collecting 16 hours after LPS injection. We found higher LPS‐induced severity in SOCS3iEKO mice compared to littermate controls. We observed significant weight loss after endotoxin, but surprisingly SOCS3iEKO mice displayed less weight loss, which could be due to fluid accumulation driven by increased systemic edema. Therefore, we interrogated whether SOCS3 loss promoted endothelial permeability. Lung and brain microvascular permeability was assayed by injecting FITC‐labeled 70kDa dextran 30 minutes prior to euthanasia and perfusion with PBS. Consistent with increased leakage, extravasated dextran was detected in thick (50‐100) um sections of LPS treated SOCS3iEKO mice. We hypothesized that this higher permeability could be due to increased leukocyte accumulation. In fact, we detected very high levels P‐selectin mRNA level in the kidneys, livers and lungs of LPS treated SOCS3iEKO mice, suggesting an increased adhesivity to leukocytes of the affected vasculature. To assess this, we stained flat mount retinas for P‐selectin and CD45 (pan‐leukocyte). LPS‐treated SOCS3iEKO mice showed a dramatic accumulation of intravascular leukocytes and increased P‐selectin expression. Intravascular leukocytes were also detected by standard H&E staining of lungs, livers and kidneys of SOCS3iEKO mice. In sum, we found that the lethality observed after a single endotoxin challenge in mice lacking endothelial SOCS3 is associated with increased intraluminal leukocyte adhesion and endothelial permeability.